Charles River Laboratories Other Non-Current Liabilities 2010-2024 | CRL
Charles River Laboratories other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Charles River Laboratories other non-current liabilities for the quarter ending December 31, 2024 were $0.237B, a 37.19% increase year-over-year.
- Charles River Laboratories other non-current liabilities for 2023 were $0.223B, a 27.67% increase from 2022.
- Charles River Laboratories other non-current liabilities for 2022 were $0.175B, a 28.02% decline from 2021.
- Charles River Laboratories other non-current liabilities for 2021 were $0.243B, a 18.34% increase from 2020.
| Charles River Laboratories Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $223 |
| 2022 | $175 |
| 2021 | $243 |
| 2020 | $205 |
| 2019 | $183 |
| 2018 | $179 |
| 2017 | $195 |
| 2016 | $159 |
| 2015 | $89 |
| 2014 | $100 |
| 2013 | $71 |
| 2012 | $105 |
| 2011 | $108 |
| 2010 | $115 |
| 2009 | $122 |
| Charles River Laboratories Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2024-09-30 | $237 |
| 2024-06-30 | $225 |
| 2024-03-31 | $235 |
| 2023-12-31 | $223 |
| 2023-09-30 | $173 |
| 2023-06-30 | $177 |
| 2023-03-31 | $187 |
| 2022-12-31 | $175 |
| 2022-09-30 | $195 |
| 2022-06-30 | $195 |
| 2022-03-31 | $239 |
| 2021-12-31 | $243 |
| 2021-09-30 | $214 |
| 2021-06-30 | $207 |
| 2021-03-31 | $207 |
| 2020-12-31 | $205 |
| 2020-09-30 | $184 |
| 2020-06-30 | $176 |
| 2020-03-31 | $174 |
| 2019-12-31 | $183 |
| 2019-09-30 | $171 |
| 2019-06-30 | $181 |
| 2019-03-31 | $174 |
| 2018-12-31 | $179 |
| 2018-09-30 | $185 |
| 2018-06-30 | $197 |
| 2018-03-31 | $205 |
| 2017-12-31 | $195 |
| 2017-09-30 | $167 |
| 2017-06-30 | $164 |
| 2017-03-31 | $161 |
| 2016-12-31 | $159 |
| 2016-09-30 | $97 |
| 2016-06-30 | $96 |
| 2016-03-31 | $87 |
| 2015-12-31 | $89 |
| 2015-09-30 | $140 |
| 2015-06-30 | $111 |
| 2015-03-31 | $117 |
| 2014-12-31 | $100 |
| 2014-09-30 | $98 |
| 2014-06-30 | $103 |
| 2014-03-31 | $70 |
| 2013-12-31 | $71 |
| 2013-09-30 | $102 |
| 2013-06-30 | $105 |
| 2013-03-31 | $107 |
| 2012-12-31 | $105 |
| 2012-09-30 | $97 |
| 2012-06-30 | $99 |
| 2012-03-31 | $100 |
| 2011-12-31 | $108 |
| 2011-09-30 | $100 |
| 2011-06-30 | $106 |
| 2011-03-31 | $111 |
| 2010-12-31 | $115 |
| 2010-09-30 | $104 |
| 2010-06-30 | $107 |
| 2010-03-31 | $118 |
| 2009-12-31 | $122 |
| 2009-09-30 | $125 |
| 2009-06-30 | $115 |
| 2009-03-31 | $116 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.437B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $148.052B | 27.37 |
| Elevance Health (ELV) | United States | $90.846B | 11.88 |
| CVS Health (CVS) | United States | $83.717B | 12.25 |
| Cencora (COR) | United States | $47.591B | 17.27 |
| DiDi Global (DIDIY) | China | $23.087B | 0.00 |
| Natera (NTRA) | United States | $22.788B | 0.00 |
| ICON (ICLR) | Ireland | $15.783B | 14.04 |
| Doximity (DOCS) | United States | $14.316B | 74.45 |
| BioMerieux (BMXMF) | France | $14.074B | 0.00 |
| Revvity (RVTY) | United States | $13.997B | 23.47 |
| Viatris (VTRS) | United States | $13.046B | 4.02 |
| Solventum (SOLV) | United States | $12.780B | 0.00 |
| Avantor (AVTR) | United States | $12.038B | 17.68 |
| CochLear (CHEOY) | Australia | $11.471B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.479B | 27.23 |
| HealthEquity (HQY) | United States | $9.860B | 49.47 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.450B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.815B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.224B | 31.72 |
| Bausch + Lomb (BLCO) | Canada | $5.745B | 26.29 |
| Organon (OGN) | United States | $3.938B | 4.01 |
| Sotera Health (SHC) | United States | $3.861B | 20.65 |
| BrightSpring Health Services (BTSG) | United States | $3.639B | 77.41 |
| Surgery Partners (SGRY) | United States | $3.282B | 37.42 |
| GeneDx Holdings (WGS) | United States | $3.058B | 371.03 |
| Concentras Parent (CON) | United States | $2.973B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.699B | 0.00 |
| Teladoc Health (TDOC) | United States | $2.371B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.078B | 0.00 |
| Progyny (PGNY) | United States | $2.017B | 40.85 |
| PACS (PACS) | United States | $2.006B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.955B | 51.30 |
| Premier (PINC) | United States | $1.711B | 10.96 |
| Agilon Health (AGL) | United States | $1.471B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| CareDx (CDNA) | United States | $1.325B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.212B | 11.86 |
| Establishment Labs Holdings (ESTA) | $1.010B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.908B | 6.14 |
| Embecta (EMBC) | United States | $0.899B | 6.16 |
| Auna S.A (AUNA) | Luxembourg | $0.633B | 0.00 |
| DocGo (DCGO) | United States | $0.562B | 21.19 |
| Sonida Senior Living (SNDA) | United States | $0.499B | 0.00 |
| SBC Medicals (SBC) | United States | $0.483B | 0.00 |
| MultiPlan (MPLN) | United States | $0.476B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.453B | 0.00 |
| Enhabit (EHAB) | United States | $0.440B | 38.09 |
| Nutex Health (NUTX) | United States | $0.352B | 0.00 |
| LifeMD (LFMD) | United States | $0.345B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.308B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.294B | 7.71 |
| Beauty Health (SKIN) | United States | $0.210B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.183B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.144B | 0.00 |
| Biodesix (BDSX) | United States | $0.138B | 0.00 |
| So-Young (SY) | China | $0.118B | 19.98 |
| IceCure Medical (ICCM) | Israel | $0.086B | 0.00 |
| ModivCare (MODV) | United States | $0.082B | 4.46 |
| Ascend Wellness Holdings (AAWH) | United States | $0.081B | 0.00 |
| Oncology Institute (TOI) | United States | $0.073B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.60 |
| Singular Genomics Systems (OMIC) | United States | $0.051B | 0.00 |
| OncoCyte (OCX) | United States | $0.048B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.036B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.022B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.020B | 0.00 |
| KindlyMD (KDLY) | United States | $0.016B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |